CoChat

Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature

Open access
Kirova, Youlia M., Savignoni, Alexia, Sigal-Zafrani, Brigitte, de La Rochefordiere, Anne, Salmon, Rémy J., This, Pascale, Asselain, Bernard, Stoppa-Lyonnet, Dominique, Fourquet, Alain · 2010 · Breast Cancer Research and Treatment

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index; 2 of the 76 sources its claims cite were checked for support.

Abstract

As tumours in BRCA1/2 mutation carriers might be more sensitive to radiation, we investigated after long-term follow-up whether mutation status influenced the rate of ipsilateral and contralateral breast cancers after breast-conserving treatment (BCT). BRCA1 and BRCA2 genes were screened for germline mutations in 131 patients with a family history of breast and/or ovarian cancer who had undergone BCT and radiotherapy. Patients were matched to 261 controls with sporadic breast cancer according to age at diagnosis and year of treatment. Controls were followed up for at least as long as the interval between diagnosis and genetic screening in familial cases. Rates of ipsilateral and contralateral cancer between groups were compared by the log-rank test. The BRCA1/2 mutations occurred in 20.6% of tested patients. Tumours in mutation carriers were more likely to be grade III (P < 10(-4)) and oestrogen receptor negative (P = 0.005) than in non-carriers and controls. Overall median follow-up was 161 months. There was no significant difference in ipsilateral tumours between mutation carriers, non-carriers and controls (P = 0.13). On multivariate analysis, age was the most significant predictor for ipsilateral recurrence (P < 10(-3)). The rate of contralateral cancer was significantly higher in familial cases: 40.7% (mutation carriers), 20% (non-carriers), and 11% (controls) (P < 10(-4)). After 13.4 years of follow-up, the rate of ipsilateral tumours was no higher in mutation carriers…

Overview

CoChat Summary

## TL;DR

This matched retrospective single-institution study found that, after a median follow-up of 13.4 years, BRCA1/2 mutation carriers had no higher ipsilateral breast tumor recurrence after breast-conserving treatment plus radiotherapy than non-carriers or sporadic controls. However, contralateral breast cancer was significantly more common in carriers, so breast-conserving treatment remained a possible option but with caution and risk-reduction discussion.

## Key findings

  • Among 131 screened patients, 27 (20.6%) carried a BRCA mutation: 19 BRCA1 and 8 BRCA2.
  • Median follow-up was 161 months overall (167 months in carriers, 161 months in non-carriers, 156 months in controls), and there was no significant difference in ipsilateral tumor recurrence among groups (P = 0.13) or between carriers and matched controls (P = 0.43).
  • Tumors in mutation carriers were more often grade III (P < 10^-4) and hormone receptor negative (estrogen receptor P = 0.018, progesterone receptor P = 0.02) than in non-carriers or controls.
  • Contralateral breast cancer was significantly higher in BRCA carriers: 40.7% in carriers versus 20.2% in familial non-carriers versus 11.1% in sporadic controls (P < 10^-4). In multivariate analysis, BRCA mutation status was the only significant predictor of contralateral cancer (P < 10^-4), while age was the only significant predictor of local recurrence (RR 1.05 [1.02–1.07] per decreasing year of age; P < 10^-3).

## Methods

  • Retrospective matched case-control study at Institut Curie of women with small breast cancers treated with breast-conserving surgery and radiotherapy between 1981 and 2000.
  • 131 patients with a family history of breast/ovarian cancer were genetically screened; they were matched to 261 sporadic controls by age at diagnosis, year of treatment, and follow-up period.
  • Survival and recurrence outcomes were analyzed with Kaplan–Meier, log-rank tests, and Cox proportional hazards models adjusting for age, nodal status, receptor status, and grade.

## Limitations

  • The paper states the main weakness is the limited number of patients and the retrospective nature of the study.
  • Evident from the text: some analyses were limited by missing data/not determined values and the small number of events in subgroups, and the authors note that the effect of tamoxifen on contralateral risk was not studied because of the high number of receptor-negative tumors.
  • Evident from the text: the cohort is from a single institution, which may limit generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s10549-009-0685-6

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
From the PDF
Fig. 2 Contralateral tumour free interval: a BRCA1/2 mutations carriers versus non-carriers versus sporadic controls, b BRCA1/2 mutation carriers versus their matched sporadic controls
Fig. 2 Contralateral tumour free interval: a BRCA1/2 mutations carriers versus non-carriers versus sporadic controls, b BRCA1/2 mutation carriers versus their matched sporadic controlsFrom the PDF

Verification

Claims the paper makes

2 Valid · 1 Not valid · 19 Not checked · 27 Own results and interpretations

24 more claims

Create a free account to see all 49 claims and to verify the 74 references still open.

See all claims — free account
  • It may state two separate claims as one. 10
  • Probably not a substantial claim. 13

Create a free account to see these claims.

Citations

Cites

Show all 58 references

Cited by

See all 102

Metadata

Authors
Kirova, Y. M., Savignoni, A., Sigal-Zafrani, B., de La Rochefordiere, A., Salmon, R. J., This, P., Asselain, B., Stoppa-Lyonnet, D., & Fourquet, A.
Affiliations
Institut Curie (FR)
Corresponding author
Kirova, Youlia M.
Venue
Breast Cancer Research and Treatment
Published
2009-12-24
Volume
120
Issue
1
Pages
119-126
ISSN
  • 0167-6806 (ISSN-L)
  • 1573-7217
OpenAlex
W2072876845
Cited by
102
References
58
Citations by year
2026: 3 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 6 · 2021: 11 · 2020: 9 · 2019: 10 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 7 · 2014: 8 · 2013: 9 · 2012: 6
FWCI
0.66
Type
journal article
Language
en
Open access
Licence
  • other-oa
  • www.springer.com/tdm (tdm)
Locations
  • Breast Cancer Research and Treatment (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • Trinity's Access to Research Output (TARA) (Trinity College Dublin) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
Keywords
breast-conserving therapy, BRCA1 mutation, BRCA2 mutation, germline mutation carriers, radiotherapy, ipsilateral breast cancer recurrence, contralateral breast cancer, radiosensitivity, hereditary breast cancer, tumor grade, long-term follow-up
MeSH terms
Adult, Age Factors, Breast Neoplasms, Combined Modality Therapy, Female, Heterozygote, Humans, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Retrospective Studies, Mastectomy, Segmental, Incidence, Case-Control Studies, Neoplasms, Second Primary, Disease-Free Survival, Genes, BRCA1, Genes, BRCA2, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. https://app.cochat.ai/papers/10.1007/s10549-009-0685-6
The paper
Kirova, Y. M., Savignoni, A., Sigal-Zafrani, B., de La Rochefordiere, A., Salmon, R. J., This, P., Asselain, B., Stoppa-Lyonnet, D., & Fourquet, A. (2010). Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-009-0685-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.